Ovarian Cancer section

Ovarian Cancer News & Features

Beta-blockers may improve survival in epithelial ovarian cancer

Beta-blockers may improve survival in epithelial ovarian cancer

Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.

Carboplatin plus paclitaxel improves quality of life in ovarian cancer

Carboplatin plus paclitaxel improves quality of life in ovarian cancer

There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.

RAD51 mutations confer moderate ovarian cancer risk

RAD51 mutations confer moderate ovarian cancer risk

RAD51C and RAD51D deleterious mutations have been linked to increased risk of epithelial ovarian cancer.

Combination therapy inhibits resistance and recurrence in ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but researchers are investigating why it frequently returns after treatment.

Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management

Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management

Multigene testing for hereditary breast and/or ovarian cancer that tests is more likely to inform clinical decision-making than testing for BRCA1/2 alone.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs